ANDAnd License Agreement • September 30th, 2004 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations • New Jersey
PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT Between Zymeworks Inc. and GlaxoSmithKline Intellectual Property Development Limited April 21, 2016 ConfidentialAnd License Agreement • April 3rd, 2017 • Zymeworks Inc. • Pharmaceutical preparations • Delaware
THIS PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (the “Agreement”), effective as of 21 April, 2016 (the “Effective Date”), by and between GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, a corporation organized and existing under the laws of England and Wales, with its registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”) and ZYMEWORKS INC., a corporation organized and existing under the laws of Canada, and extraprovincially in British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”). Zymeworks and GSK are each referred to individually as a “Party” and together as the “Parties”.
RESEARCH COLLABORATION, PRODUCT DEVELOPMENT AND LICENSE AGREEMENT by and between NGM BIOPHARMACEUTICALS, INC. and MERCK SHARP & DOHME CORP.And License Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Research Collaboration, Product Development and License Agreement (this “Agreement”) is effective as of February 18, 2015 (the “Execution Date”), and is entered into by and between NGM BIOPHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“NGM”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of Delaware (“Merck”). Each of Merck and NGM may be referred to herein individually as a “Party” and collectively as “Parties.”
AUTHORSHIP, MEMBERSHIP, DISCLOSURE STATEMENTS, COPYRIGHT, AND LICENSE AGREEMENTAnd License Agreement • November 2nd, 2020
This AUTHORSHIP, MEMBERSHIP, DISCLOSURE STATEMENTS, COPYRIGHT, AND LICENSE AGREEMENT encompasses all aspects related to our original cover page, acknowledgement and ethical consideration statements, account details, declarations, and publication license forms. All fields are to be completed and submitted to AOSIS as a supplementary document, at the manuscript submission point, onto the journal website.
THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND LICENSE AGREEMENTAnd License Agreement • November 2nd, 2015 • Mesoblast LTD • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (the “Amendment”) effective as of October 27, 2003 (“Amendment Effective Date”), by and between Case Western Reserve University, an Ohio nonprofit corporation having a place of business at 10900 Euclid Avenue, Cleveland, OH 44106 (“CWRU”) and Osiris Therapeutics, Inc., a Delaware corporation with an address at 2001 Aliceanna Street, Baltimore, Maryland 21231-3043 (“OSIRIS”), in exchange for their mutual covenants herein set forth, hereby agree as follows:
Portfolio Support and License AgreementAnd License Agreement • February 3rd, 2022 • Guggenheim Defined Portfolios, Series 2202 • Illinois
This Agreement, dated as of February 3, 2022, is made by and between ARK Investment Management LLC, a Delaware limited liability company with its principal place of business at 3 East 28th Street, Seventh Floor, New York, NY 10016 (“Licensor”), and Guggenheim Funds Distributor, LLC., (“GFD”) as sponsor to, ARK Early Stage Disruptors Portfolio, CDA Series 2022 Q1 (the “Trust”).
AMENDED AND RESTATED DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of 31 March 2011And License Agreement • May 10th, 2011 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Amended and Restated Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of 31 March 2011 (the “Amendment Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai – 400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT between ISIS PHARMACEUTICALS, INC. and AKCEA THERAPEUTICS, INC.And License Agreement • March 27th, 2017 • Akcea Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, COMERCIALIZATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of December 18, 2015 (the “Effective Date”), by and between AKCEA THERAPEUTICS, INC., a Delaware corporation (“Akcea”), and ISIS PHARMACEUTICALS, INC., a Delaware corporation (“Isis”). Akcea and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Copyright and License AgreementAnd License Agreement • March 2nd, 2023
When transmitting your paper or presentation video (hereinafter also: “contribution”) to the Mesago Messe Frankfurt Conference Department you confirm that you took notice of and specifically acknowledge this copyright and license agreement. As author (co-author) you especially assure to dispose of the exclusive copyright in the transmitted paper or presentation video.
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between RENOVIS, INC. and GENENTECH, INC.And License Agreement • February 3rd, 2004 • Renovis Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of December 31, 2003 (the “Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”), with offices at Two Corporate Drive, South San Francisco, CA 94080, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Renovis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED RESEARCH COLLABORATION AND...And License Agreement • September 9th, 2019 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of July 20, 2018 (the “Execution Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and BioNTech RNA Pharmaceuticals GmbH, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech RNA”) and BioNTech AG, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech AG”). BioNTech RNA and BioNTech AG are collectively referred to herein as “BioNTech”).Pfizer and BioNTech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Portfolio Support and License AgreementAnd License Agreement • February 4th, 2021 • Guggenheim Defined Portfolios, Series 2112 • Illinois
This Agreement, dated as of February 4th, 2021 is made by and between Flaherty & Crumrine Incorporated, a California corporation (“Consultant/Licensor”), and Guggenheim Funds Distributors, LLC., (“Guggenheim” or “Licensee”) as sponsor to, Flaherty & Crumrine Preferred Portfolio, Series 52 (the “Trust”).
MANUFACTURING, SUPPLY, AND LICENSE AGREEMENT, and License Agreement • September 15th, 2009 • Encision Inc • Surgical & medical instruments & apparatus • California
This Manufacturing, Supply, and License Agreement (the “Agreement”) is made on this 30th day of March 2009, (the “Effective Date”) by and between INTUITIVE SURGICAL INC., (hereinafter, “Intuitive”) a Delaware corporation with its principal place of business located at 1266 Kifer Road, Sunnyvale, California 94086, and ENCISION, INC. (hereinafter, “Encision”), a Colorado corporation with its principal place of business located at 6797 Winchester Circle, Boulder, CO 80301. Intuitive and Encision hereby agree to the following terms and conditions for the performance of this Agreement.
LICENSE AGREEMENTAnd License Agreement • May 7th, 2018 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT, COMMERCIALIZATION, COLLABORATION, AND LICENSE AGREEMENT is made and entered into as of March 14, 2018 (the “Execution Date”), by and between Akcea Therapeutics, Inc., a Delaware corporation (“Akcea”), and Ionis Pharmaceuticals, Inc., a Delaware corporation (“Ionis”). Akcea and Ionis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between CURIS, INC. and GENENTECH, INC.And License Agreement • August 6th, 2015 • Curis Inc • Biological products, (no disgnostic substances) • California
AMENDMENT NO. 1 TO THE RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENTAnd License Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO THE RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT (the “Amendment No. 1”) is made this 28th day of July, 2011 (the “Amendment No. 1 Effective Date”) by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”) and GlaxoSmithKline LLC, a Delaware limited liability company with a principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19102, United States of America (formerly known as SmithKline Beecham Corporation) (“GSK”). OncoMed and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc.And License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Research Collaboration and License Agreement (the “Agreement”) is effective as of July 29, 2010 (the “Effective Date”) and is entered into by and between GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at 1650 Owens Street, Suite 200, San Francisco, CA (“FivePrime”). GSK and FivePrime are referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT BY AND BETWEEN ONCOMED PHARMACEUTICALS, INC. AND SMITHKLINE BEECHAM CORPORATION DECEMBER 7, 2007And License Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS RESEARCH AND DEVELOPMENT COLLABORATION, OPTION, AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of December 7, 2007 (the “Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and SmithKline Beecham Corporation, a Pennsylvania corporation doing business as GlaxoSmithKline with a principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19102, United States of America (“GSK”). OncoMed and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT July 10, 2009And License Agreement • April 5th, 2010 • Codexis Inc • Industrial organic chemicals • New York
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT, together with schedules attached hereto (this “Agreement”) is entered into and effective as of July 10, 2009 (the “Effective Date”) by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America, (“Codexis”), Iogen Energy Corporation, a corporation existing under the law of Canada, having a place of business at 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1, Canada, (“IE”), Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002, (“Shell US”), and Shell Chemicals Canada Limited, a corporation existing under the laws of Canada, having a place of business at 400 - 4th Avenue S.W., P.O. Box 4280, Station ‘C’, Calgary, Alberta T2T 5Z5, Canada (“Shell Canada” and together with Shell US “Shell”). Codexis, IE, Shell US and Shell Canada may
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. and ALLERGAN SALES, LLCAnd License Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of March 27, 2003 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively “Allergan”), both having offices at 2525 Dupont Drive, Irvine, California 92612.
AND LICENSE AGREEMENTAnd License Agreement • February 2nd, 2010 • Senomyx Inc • Services-commercial physical & biological research
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. (“Senomyx”) and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes, 1211 Geneva 8, Switzerland (“Firmenich”).
AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN SENOMYX, INC. AND PEPSICO, INC.And License Agreement • March 21st, 2017 • Senomyx Inc • Services-commercial physical & biological research • Delaware
This Amended and Restated Agreement (the “Agreement”) is entered into as of September 30, 2016 (the “Amended Effective Date”) by and between SENOMYX, INC., a Delaware Corporation having its principal place of business at 4767 Nexus Centre Drive, San Diego, CA 92121 (“SENOMYX”) and PEPSICO, INC., a North Carolina Corporation, having its principal place of business at 700 Anderson Hill Road, Purchase, NY 10577 (“PEPSICO”).
AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN SENOMYX, INC. AND FIRMENICH SAAnd License Agreement • March 8th, 2018 • Senomyx Inc • Services-commercial physical & biological research
THIS AMENDED AND RESTATED AGREEMENT is entered into as of February 7, 2018, by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. (“Senomyx”) and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes, 1211 Geneva 8, Switzerland (“Firmenich”).
DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTAnd License Agreement • October 31st, 2000 • Corixa Corp • Biological products, (no disgnostic substances) • Arizona
THIRD AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENTAnd License Agreement • November 2nd, 2005 • Senomyx Inc • Services-commercial physical & biological research • California
THIS THIRD AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Third Amendment”) is made by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 11099 North Torrey Pines Road, La Jolla, California 92037, and KRAFT FOODS GLOBAL, INC., a Delaware corporation (“Kraft”) having offices at 801 Waukegan Road, Glenview, IL 60025.
STAIRMASTER TECHNOLOGY TRANSFER AND LICENSE AGREEMENTAnd License Agreement • March 8th, 2010 • Nautilus, Inc. • Sporting & athletic goods, nec
THIS STAIRMASTER TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (hereinafter “Stairmaster Technology Agreement” or “Agreement”) relates to technology connected with the Nautilus Stairmaster business and is effective as of the date of signing by the last of the parties to sign below and is by and between Xiamen World Gear Sports Goods Co., Ltd. a corporation organized under the laws of the People’s Republic of China (“Buyer”), having a place of business at 27-29 North 2nd Road, Xinglin, Jimei District, Xiamen City, Fujian Province, People’s Republic of China and Nautilus, Inc. (“Nautilus”), a Washington corporation, having a place of business at 16400 SE Nautilus Drive, Vancouver, WA. 98683. Buyer and Nautilus are referred to collectively herein as the “Parties”. This Stairmaster Technology Agreement is an exhibit to a Stairmaster Asset Purchase Agreement relating to the Nautilus Stairmaster business entered into on the same date between Buyer and Nautilus. The parties agree as follows:
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between CURIS, INC. and GENENTECH, INC.And License Agreement • July 10th, 2003 • Curis Inc • Biological products, (no disgnostic substances) • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of June 11, 2003 (the “Effective Date”), by and between CURIS, INC., a Delaware corporation (“Curis”), with offices at 61 Moulton Street, Cambridge, Massachusetts 02138, on behalf of itself and its Affiliates, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Curis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTAnd License Agreement • February 5th, 2021 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Third Amendment”) is entered into as of October 20, 2014, by and between Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”) and AbbVie Inc., having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064 (“AbbVie”). AbbVie and Enanta are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Portfolio Support and License AgreementAnd License Agreement • November 15th, 2023 • Guggenheim Defined Portfolios, Series 2364 • Illinois
This Portfolio Support and License Agreement (the “Agreement”), dated as of November 8, 2023, is made by and between abrdn Inc., a Delaware corporation (“Consultant/Licensor”), and Guggenheim Funds Distributor, LLC., (“GFD” or “Licensee”) as sponsor to, abrdn Medical Science Innovation Portfolio Series 7 (the “Trust”).
SIXTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENTAnd License Agreement • November 2nd, 2007 • Senomyx Inc • Services-commercial physical & biological research • California
THIS SIXTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Sixth Amendment”) is entered into as of July 18, 2007 (the “Sixth Amendment Effective Date”) by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 4767 Nexus Centre Drive, San Diego, California 92121, and KRAFT FOODS GLOBAL, INC., a Delaware corporation (“Kraft”) having offices at 801 Waukegan Road, Glenview, IL 60025.
AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENTAnd License Agreement • August 8th, 2019 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This AMENDMENT NO. 1 to the SECOND AMENDED AND RESTATED STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Amendment”) is entered into as of May 2, 2019 (the “Amendment Effective Date”) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Ionis”), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). Biogen and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTAnd License Agreement • February 4th, 2010 • Senomyx Inc • Services-commercial physical & biological research
THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (the “First Amendment”) is made by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 4767 Nexus Centre Drive, San Diego, CA 92121, and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes,1211 Geneva 8, Switzerland (“Firmenich”).
AND LICENSE AGREEMENTAnd License Agreement • January 8th, 2021
I, parent/legal guardian of (“Child”), irrevocably grant to Make-A-Wish Foundation® of America and all licensed chapters and affiliates thereof (collectively, “Foundation”) the authorization and right to use my Child’s likeness, whether embodied in photographs, videotapes, recordings or any other format (collectively, “Depictions”), for purposes of promotion, publication, commercial advertising or any other purpose, now or at any time in the future.
COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENTAnd License Agreement • August 9th, 2007 • Senomyx Inc • Services-commercial physical & biological research • Delaware
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. (“Senomyx”) and SOLAE, LLC, a Delaware Limited Liability Corporation, having its principal place of business at 1034 Danforth Drive, St. Louis, Missouri, USA 63102 (“Solae”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([*]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE EXCHANGE ACT OF 1934, AS AMENDED RESEARCH...And License Agreement • May 11th, 2009 • Combinatorx, Inc • Pharmaceutical preparations • Massachusetts
This Research Collaboration and License Agreement (this “Agreement”) is dated as of May 1, 2009 (the “Effective Date”), by and between CombinatoRx, Incorporated, a Delaware corporation with principal offices at 245 First Street, Fourth Floor, Cambridge, MA 02142 (“CombinatoRx”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation with principal offices at 250 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
